Exactech Announces Successful First Surgeries with New Equinoxe® Preserve Stem and ExactechGPS® Shoulder Application
06 June 2017 - 10:30PM
Business Wire
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone
and joint restoration products and biologic solutions for
extremities, knee and hip, announced today a successful first
surgery using the new Equinoxe® Preserve stem, a conservative
shoulder treatment option designed to preserve humeral bone in
shoulder replacement surgery. Additionally, surgeons performed the
first U.S. procedures using the ExactechGPS® Shoulder
Application.
Orthopaedic surgeon Thomas Wright, MD, performed the first
Preserve stem surgery in Gainesville, Fla. “The surgical team and I
were pleased with the results of today’s surgery, including the
thoughtful implant design, practical instrumentation and relatively
simple technique,” Dr. Wright said.
The Preserve stem expands the options offered by the successful
Equinoxe® Platform Shoulder System. This new stem is approximately
two-thirds the length of the system’s current stem.
“Creating a bone preserving stem that can be used alongside
already clinically successful components of our Equinoxe anatomic
and reverse implants is an important evolutionary step in our
perpetual pursuit of improved clinical outcomes,” said Darin
Johnson, Vice President of Marketing, Extremities.
The implant design was developed through the use of CT
reconstruction data and clinical studies. Specifically, the implant
features a unique polished distal tip to facilitate any need for
removal, a straight lateral fin designed for greater rotational
stability and plasma coating to aid proximal fixation.
“The technique and implant were created to provide a more bone
preserving option within the Equinoxe suite. It was a great
pleasure over the last couple of years to collaborate with Drs.
Samuel Antuna, Ken Faber, Howard Routman, Joseph Zuckerman and
Pierre-Henri Flurin on this innovative improvement. This product
demonstrates Exactech’s commitment to working closely with surgeons
to improve patient outcomes,” Dr. Wright said.
Dr. Wright and Richard Jones, MD, of Asheville, N.C., also
completed the first U.S. surgeries using the ExactechGPS Shoulder
Application, a computer-assisted shoulder arthroplasty technology.
“This advance in shoulder arthroplasty - being able to execute a
preoperative plan in the operating room with real-time visibility
into the glenoid vault - has almost limitless possibilities to help
patients. Ten years ago, Dr. Sean Grey and I implanted the first
Equinoxe reverse shoulder, and that innovation set the pace for the
last decade. Now, I believe, ExactechGPS is the breakthrough for
the next decade,” Dr. Jones said.
Full U.S. market availability for the Preserve Stem and
ExactechGPS Shoulder Application is planned for the beginning of
2018.
About Exactech
Based in Gainesville, Fla., Exactech develops and markets
orthopaedic implant devices, related surgical instruments and
biologic materials and services to hospitals and physicians. The
company manufactures many of its orthopaedic devices at its
Gainesville facility. Exactech’s orthopaedic products are used in
the restoration of bones and joints that have deteriorated as a
result of injury or diseases such as arthritis. Exactech markets
its products in the United States, in addition to more than 30
markets in Europe, Latin America, Asia and the Pacific. Additional
information about Exactech can be found
at http://www.exac.com.
A current investment profile on Exactech (Nasdaq: EXAC) is
available online
at http://www.hawkassociates.com/profile/exac.cfm. To receive
future releases in e-mail alerts, sign up
at http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, which represent
the company’s expectations or beliefs concerning future events of
the company’s financial performance. These forward-looking
statements are further qualified by important factors that could
cause actual results to differ materially from those in the
forward-looking statements. These factors include the effect of
competitive pricing, the company’s dependence on the ability of
third party manufacturers to produce components on a basis which is
cost-effective to the company, market acceptance of the company’s
products and the effects of government regulation. Results actually
achieved may differ materially from expected results included in
these statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170606005231/en/
ExactechInvestor contacts:Jody Phillips, 352-377-1140Executive
Vice President of Finance & Chief Financial OfficerorHawk
AssociatesJulie Marshall or Frank Hawkins,
305-451-1888EXAC@hawkassociates.comorExactechMedia
contact:Priscilla Bennett, 352-377-1140Vice President, Corporate
& Marketing Communication
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Apr 2024 to May 2024
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From May 2023 to May 2024